Paul Tudor Jones Atara Biotherapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$2.85 - $5.18 $106,453 - $193,483	-37,352 Reduced 16.93%	183,283 $601,000
Q3 2022 Nov 14, 2022	BUY	$2.85 - $8.73 $377,944 - $1.16 Million	132,612 Added 150.66%	220,635 $834,000
Q2 2022 Aug 15, 2022	BUY	$4.69 - $9.84 $187,515 - $393,422	39,982 Added 83.22%	88,023 $686,000
Q1 2022 May 16, 2022	BUY	$8.44 - $16.89 $405,466 - $811,412	48,041 New	48,041 $446,000
Q1 2021 May 17, 2021	SELL	$14.0 - $20.72 $197,330 - $292,048	-14,095 Closed	0 $0

Q4 2020 Feb 16, 2021	SELL	$12.67 - $26.23 $47,107 - $97,523	-3,718 Reduced 20.87%	14,095 $277,000
Q3 2020 Nov 16, 2020	BUY	$11.92 - $15.87 $212,330 - $282,692	17,813 New	17,813 $231,000
Q2 2020 Aug 14, 2020	SELL	$7.53 - $14.93 $572,023 - $1.13 Million	-75,966 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$5.69 - $17.78 $180,532 - $564,123	31,728 Added 71.72%	75,966 $646,000
Q4 2019 Feb 14, 2020	BUY	$10.89 - $16.79 $481,751 - $742,756	44,238 New	44,238 $729,000

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $728M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.